让中成药安全的“标尺”更清晰

Core Viewpoint - Recent regulatory requirements for traditional Chinese medicine (TCM) aim to enhance the safety and clarity of drug information, addressing consumer concerns about the potential elimination of many TCM products [1][2] Group 1: Regulatory Changes - Starting from July 1, 2026, TCM products with unclear contraindications, adverse reactions, and precautions will not be approved for re-registration, raising the standards for TCM safety [1] - The new regulations will end the previous system where TCM approvals were only additive, promoting a competitive environment that prioritizes quality over quantity [2] Group 2: Industry Impact - The requirement for clearer labeling will provide scientific guidance for doctors and improve public awareness of medication risks, thereby enhancing the overall safety of TCM usage [1] - The regulatory changes are expected to drive a systemic transformation across the entire TCM industry, from drug labeling to pricing and production standards, fostering a shift towards evidence-based practices [2] Group 3: Corporate Responsibility - Companies are now compelled to take greater responsibility for drug safety and efficacy, necessitating the improvement of safety data and the revision of product information [1] - The emphasis on quality and safety will encourage TCM enterprises to strengthen post-market research and ensure compliance with updated standards [1][2]